Michael Lee Milligan - 14 Sep 2023 Form 3 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Title: SVP Finance & Principal Accounting Officer; Exhibit 24 - Power of Attorney
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Michael Lee Milligan
Issuer symbol
NMRA
Transactions as of
14 Sep 2023
Net transactions value
$0
Form type
3
Filing time
18 Sep 2023, 15:11:35 UTC
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NMRA Common Stock 3,823 14 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 85,390 $4.63 Direct F1, F2
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 38,234 $6.52 Direct F1, F3
holding NMRA Stock Option (Right to Buy) 14 Sep 2023 Common Stock 28,675 $6.36 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects a 1-for-7.8463 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement on September 8, 2023.
F2 25% of the shares subject to the option vest on the first anniversary measured from December 20, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F3 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F4 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: SVP Finance & Principal Accounting Officer; Exhibit 24 - Power of Attorney